Literature DB >> 2229781

Direct visualization of ruptured chordae tendineae by transesophageal two-dimensional echocardiography.

T Hozumi1, J Yoshikawa, K Yoshida, Y Yamaura, T Akasaka, M Shakudo.   

Abstract

To determine the value of transesophageal echocardiography in the detection of ruptured chordae tendineae, 28 patients who had surgical therapy for pure mitral regurgitation were evaluated prospectively by conventional transthoracic and transesophageal two-dimensional echocardiography. Seventeen patients (Group I) had ruptured chordae tendineae and 11 (Group II) had intact chordae tendineae. Transthoracic echocardiography detected ruptured chordae tendineae in 6 patients from Group I (sensitivity 35%) and flail leaflets in 11 patients from Group I (sensitivity 65%). Transesophageal echocardiography disclosed ruptured chordae tendineae in all 17 Group I patients (sensitivity 100%); the sensitivity was significantly higher than that of transthoracic echocardiography. No abnormal chordal echoes were visualized in any patient from Group II by either transthoracic or transesophageal echocardiography (specificity 100%). Transesophageal echocardiography is a highly sensitive method for detecting ruptured chordae tendineae and is superior to transthoracic echocardiography in establishing its diagnosis.

Entities:  

Mesh:

Year:  1990        PMID: 2229781     DOI: 10.1016/0735-1097(90)90571-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  2 in total

1.  Critical tricuspid regurgitation secondary to ruptured chordae tendineae mimicking a mass on the tricuspid valve in a newborn.

Authors:  S Atalay; A Imamoglu; O Uluoglu; C Ikizler
Journal:  Pediatr Cardiol       Date:  1995 May-Jun       Impact factor: 1.655

2.  Acute severe mitral regurgitation: consideration of papillary muscle architecture.

Authors:  Andrew Czarnecki; Amar Thakrar; Tielan Fang; Matthew Lytwyn; Roien Ahmadie; Edward Pascoe; Davinder S Jassal
Journal:  Cardiovasc Ultrasound       Date:  2008-01-18       Impact factor: 2.062

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.